|
[Biological agents and tofacitinib in rheumatoid arthritis] |
Gonzalez L, López A, Secco A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gonzalez L, López A, Secco A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Biological agents and tofacitinib in rheumatoid arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 521. 2017 Authors' conclusions High-quality evidence shows that adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab, rituximab and tofacitinib, are effective in controlling rheumatoid arthritis activity and improving the physical function of those patients with active disease and inadequate response or intolerance to standard disease-modifying drugs. There is no clear evidence that any of these drugs is better than the other.
Most of the clinical practice guidelines recommend its indication in patients with moderate to severe active disease, who have failed or are intolerant to one or more standard drugs and for some of them, when there is inadequate response to a first biological agent. The health sponsors surveyed cover all or most of these therapies in these groups of patients. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Arthritis, Rheumatoid; Biological Factors; Humans; Piperidines; Pyrimidines; Pyrroles Language Published Spanish Country of organisation Argentina English summary There is no English language summary available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32017000286 Date abstract record published 13/06/2017 |
|
|
|